Fed officials say debt downgrade complicates inflation outlook, Nvidia CEO discusses China chip ban, JPMorgan’s investor day, ...

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Regeneron develops new medicines and it rang up $3.7 billion in sales for its anti-inflammatory drug Dupixent as a treatment for eczema, asthma and chronic obstructive pulmonary disease, in its latest ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...

Regeneron (REGN) stock was upgraded to Buy and AbbVie (ABBV) stock was downgraded at Citi based on policy risks under Trump's drug reforms. Read more here.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen ...